"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Descriptor ID |
D004311
|
MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 23 | 23 |
1995 | 0 | 27 | 27 |
1996 | 0 | 31 | 31 |
1997 | 0 | 34 | 34 |
1998 | 0 | 29 | 29 |
1999 | 0 | 33 | 33 |
2000 | 0 | 30 | 30 |
2001 | 0 | 40 | 40 |
2002 | 0 | 31 | 31 |
2003 | 0 | 42 | 42 |
2004 | 0 | 37 | 37 |
2005 | 0 | 43 | 43 |
2006 | 0 | 47 | 47 |
2007 | 0 | 49 | 49 |
2008 | 0 | 51 | 51 |
2009 | 0 | 50 | 50 |
2010 | 0 | 39 | 39 |
2011 | 0 | 60 | 60 |
2012 | 0 | 55 | 55 |
2013 | 0 | 50 | 50 |
2014 | 0 | 57 | 57 |
2015 | 0 | 46 | 46 |
2016 | 0 | 51 | 51 |
2017 | 0 | 48 | 48 |
2018 | 0 | 53 | 53 |
2019 | 0 | 58 | 58 |
2020 | 0 | 47 | 47 |
2021 | 0 | 45 | 45 |
2022 | 0 | 26 | 26 |
2023 | 0 | 22 | 22 |
2024 | 0 | 21 | 21 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clin Infect Dis. 2024 Aug 16; 79(2):354-363.
-
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 2024 Jul 25; 23(Suppl 1):1250.
-
The Association Between Tranexamic Acid and Seizures in Moderate or Severe Traumatic Brain Injury. J Surg Res. 2024 Sep; 301:359-364.
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.
-
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. J Crohns Colitis. 2024 May 31; 18(5):695-707.
-
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719.
-
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA. 2024 05 28; 331(20):1714-1721.
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
-
Randomized Placebo-Controlled Trial of 60-Day Percutaneous Peripheral Nerve Stimulation Treatment Indicates Relief of Persistent Postoperative Pain, and Improved Function After Knee Replacement. Neuromodulation. 2024 Jul; 27(5):847-861.
-
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 Jun; 41(6):2500-2518.